PMC8602046_01
Clinical response to tyrosine kinase inhibitor therapy as shown by peripheral eosinophil percentage over time with treatment.
gr1.jpg
PMC8602046_01_gr1.jpg
fig0001
Dose-reduction resulted in eventual rise in eosinophils indicating ineffectiveness at lower doses (Fig. 1).Therapy was then changed to dasatinib 140 mg daily based on reports demonstrating effectiveness of dasatinib in blocking growth and survival of eosinophils. The patient continued on dasatinib with excellent response (Fig. 1) and remission for 9 months, until he was hospitalized for worsening dyspnea.